{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T10:12:52Z","timestamp":1783851172828,"version":"3.55.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01030","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T14:17:05Z","timestamp":1539008225000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Repurposing of Bromocriptine for Cancer Therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Ean-Jeong","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Johannes","family":"Greten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4158\/EP09221.OR","article-title":"Giant prolactinoma and effectiveness of medical management.","volume":"16","author":"Acharya","year":"2010","journal-title":"Endocr. Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.15252\/emmm.201606660","article-title":"Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations.","volume":"9","author":"Ajore","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1158\/0008-5472.CAN-07-2120","article-title":"Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen.","volume":"68","author":"Amundson","year":"2008","journal-title":"Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs.","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI11991","article-title":"Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.","volume":"107","author":"Baldwin","year":"2001","journal-title":"J. Clin. Invest."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1158\/1535-7163.MCT-08-0321","article-title":"Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin.","volume":"7","author":"Bednarski","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1021\/ci400284v","article-title":"Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery of amiodarone and bromocriptine inhibitory effects.","volume":"53","author":"Bellera","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"B8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.brainres.2010.09.062","article-title":"Endocrine induced changes in brain function during pregnancy.","volume":"1364","author":"Brunton","year":"2010","journal-title":"Brain Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin. Endocrinol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/jcb.21856","article-title":"Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells.","volume":"105","author":"Chen","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.canlet.2007.10.003","article-title":"Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K\/Akt\/NF kappa B pathway.","volume":"259","author":"Choi","year":"2008","journal-title":"Cancer Lett."},{"key":"B12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2337\/diacare.19.6.667","article-title":"Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.","volume":"19","author":"Cincotta","year":"1996","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317706919","article-title":"NF-kappaB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer.","volume":"39","author":"Darvishi","year":"2017","journal-title":"Tumour Biol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00143","article-title":"Multifactorial modes of action of arsenic trioxide in cancer cells as analyzed by classical and network pharmacology.","volume":"9","author":"Dawood","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1535-7163.803.3.7","article-title":"Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand\/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.","volume":"3","author":"Deeb","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/sj.onc.1205240","article-title":"Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis.","volume":"21","author":"Dhanalakshmi","year":"2002","journal-title":"Oncogene"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells.","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.phymed.2011.06.008","article-title":"Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin.","volume":"18","author":"Efferth","year":"2011","journal-title":"Phytomedicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1124\/mol.64.2.382","article-title":"Molecular modes of action of artesunate in tumor cell lines.","volume":"64","author":"Efferth","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00280-007-0480-1","article-title":"Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies.","volume":"61","author":"Evans","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-6-104","article-title":"Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.","volume":"6","author":"Ezrokhi","year":"2014","journal-title":"Diabetol. Metab. Syndr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1039\/c003511d","article-title":"One-pot double intramolecular homolytic aromatic substitution routes to dialicyclic ring fused imidazobenzimidazolequinones and preliminary analysis of anticancer activity.","volume":"8","author":"Fagan","year":"2010","journal-title":"Org. Biomol. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0140-6736(88)91413-4","article-title":"Perioperative bromocriptine adjuvant treatment for operable breast cancer.","volume":"1","author":"Fentiman","year":"1988","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro.","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"B26","author":"Goldstein","year":"1980","journal-title":"Ergot Compounds and Brain Function : Neuroendocrine and Neuropsychiatric Aspects. Advances in Biochemical Psychopharmacology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","article-title":"Biochemistry of multidrug resistance mediated by the multidrug transporter.","volume":"62","author":"Gottesman","year":"1993","journal-title":"Annu. Rev. Biochem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5455\/medarh.2013.67.181-184","article-title":"Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.","volume":"67","author":"Hajder","year":"2013","journal-title":"Med. Arch."},{"key":"B29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","article-title":"Shared principles in NF-kappaB signaling.","volume":"132","author":"Hayden","year":"2008","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3892\/or.5.4.893","article-title":"A phase II study of bromocriptine in patients with androgen-independent prostate cancer.","volume":"5","author":"Horti","year":"1998","journal-title":"Oncol. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0065-230X(08)60984-7","article-title":"Cross resistance and collateral sensitivity studies in cancer chemotherapy.","volume":"7","author":"Hutchison","year":"1963","journal-title":"Adv. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1021\/np501007n","article-title":"Pharmacogenomic characterization of cytotoxic compounds from Salvia officinalis in cancer cells.","volume":"78","author":"Kadioglu","year":"2015","journal-title":"J. Nat. Prod."},{"key":"B33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.phymed.2016.01.004","article-title":"Evaluating ancient Egyptian prescriptions today: anti-inflammatory activity of Ziziphus spina-christi.","volume":"23","author":"Kadioglu","year":"2016","journal-title":"Phytomedicine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.bbrc.2012.01.090","article-title":"Expression of human ABCB5 confers resistance to taxanes and anthracyclines.","volume":"418","author":"Kawanobe","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B35","first-page":"6793","article-title":"Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.","volume":"50","author":"Kimmig","year":"1990","journal-title":"Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-016-1253-3","article-title":"Cytotoxicity of methanol extracts of 10 Cameroonian medicinal plants towards multi-factorial drug-resistant cancer cell lines.","volume":"16","author":"Kuete","year":"","journal-title":"BMC Complement. Altern. Med."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-3361-4","article-title":"Cytotoxicity of methanol extracts of Annona muricata, Passiflora edulis and nine other Cameroonian medicinal plants towards multi-factorial drug-resistant cancer cell lines.","volume":"5","author":"Kuete","year":"","journal-title":"Springerplus"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","article-title":"A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.","volume":"28","author":"Kvernmo","year":"2006","journal-title":"Clin. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/10543400701199593","article-title":"Interaction index and different methods for determining drug interaction in combination therapy.","volume":"17","author":"Lee","year":"2007","journal-title":"J. Biopharm. Stat."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.18632\/oncotarget.6773","article-title":"Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.","volume":"7","author":"Liberante","year":"2016","journal-title":"Oncotarget"},{"key":"B41","first-page":"405","article-title":"Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia.","volume":"21","author":"Lissoni","year":"2000","journal-title":"Neuro Endocrinol. Lett."},{"key":"B42","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ijc.24294","article-title":"NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.","volume":"125","author":"Lounnas","year":"2009","journal-title":"Int. J. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/BF01930467","article-title":"Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics.","volume":"48","author":"Meier","year":"1992","journal-title":"Experientia"},{"key":"B44","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.","volume":"303","author":"Millan","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cr.2010.178","article-title":"Crosstalk of reactive oxygen species and NF-kappaB signaling.","volume":"21","author":"Morgan","year":"2011","journal-title":"Cell Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1096\/fasebj.12.10.905","article-title":"Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.","volume":"12","author":"Muralikrishnan","year":"1998","journal-title":"FASEB J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3402\/jmahp.v1i0.21131","article-title":"Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature.","volume":"1","author":"Murteira","year":"2013","journal-title":"J. Mark. Access Health Policy"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.","volume":"267","author":"O\u2019Brien","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes.","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"B50","first-page":"701","article-title":"Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson\u2019s disease.","volume":"57","author":"Radad","year":"2005","journal-title":"Pharmacol. Rep."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176910","article-title":"Prolactin-induced neuroprotection against glutamate excitotoxicity is mediated by the reduction of [Ca2+]i overload and NF-kappa B activation.","volume":"12","author":"Rivero-Segura","year":"2017","journal-title":"PLoS One"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","article-title":"Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells.","volume":"149","author":"Sachlos","year":"2012","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jnutbio.2014.09.008","article-title":"Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking.","volume":"26","author":"Saeed","year":"2015","journal-title":"J. Nutr. Biochem."},{"key":"B54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev.physiol.70.120806.095256","article-title":"The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation.","volume":"70","author":"Sandoval","year":"2008","journal-title":"Annu. Rev. Physiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/73439","article-title":"A gene expression database for the molecular pharmacology of cancer.","volume":"24","author":"Scherf","year":"2000","journal-title":"Nat. Genet."},{"key":"B56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/BF03350096","article-title":"Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas.","volume":"11","author":"Schettini","year":"1988","journal-title":"J. Endocrinol. Invest."},{"key":"B57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0960-7404(00)00012-8","article-title":"The role of NF-kappaB\/IkappaB proteins in cancer: implications for novel treatment strategies.","volume":"8","author":"Schwartz","year":"1999","journal-title":"Surg. Oncol."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035584","article-title":"Factors determining sensitivity and resistance of tumor cells to arsenic trioxide.","volume":"7","author":"Sertel","year":"2012","journal-title":"PLoS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1349-7006.2002.tb01260.x","article-title":"Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells.","volume":"93","author":"Shiraki","year":"2002","journal-title":"Jpn. J. Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00002826-200109000-00001","article-title":"Choosing dopamine agonists in Parkinson\u2019s disease.","volume":"24","author":"Tan","year":"2001","journal-title":"Clin. Neuropharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1523\/JNEUROSCI.21-09-03207.2001","article-title":"Anxiolytic and anti-stress effects of brain prolactin: improved efficacy of antisense targeting of the prolactin receptor by molecular modeling.","volume":"21","author":"Torner","year":"2001","journal-title":"J. Neurosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/leu.2010.2","article-title":"NF-kappaB activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia.","volume":"24","author":"Tracey","year":"2010","journal-title":"Leukemia"},{"key":"B63","first-page":"1105","article-title":"Dopamine agonist therapy in hyperprolactinemia.","volume":"44","author":"Webster","year":"1999","journal-title":"J. Reprod. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1185\/03007998609111089","article-title":"The safety of bromocriptine in long-term use: a review of the literature.","volume":"10","author":"Weil","year":"1986","journal-title":"Curr. Med. Res. Opin."},{"key":"B65","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1126\/science.275.5298.343","article-title":"An information-intensive approach to the molecular pharmacology of cancer.","volume":"275","author":"Weinstein","year":"1997","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/jnci\/89.20.1505","article-title":"Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.","volume":"89","author":"Wosikowski","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"B67","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1615\/CritRevImmunol.v29.i3.40","article-title":"The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs.","volume":"29","author":"Wu","year":"2009","journal-title":"Crit. Rev. Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1046\/j.1471-4159.1994.62031034.x","article-title":"Antioxidant properties of bromocriptine, a dopamine agonist.","volume":"62","author":"Yoshikawa","year":"1994","journal-title":"J. Neurochem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s10637-014-0098-1","article-title":"The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein\u2013a well-known, yet poorly understood drug transporter.","volume":"32","author":"Zeino","year":"2014","journal-title":"Invest. New Drugs"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T15:56:06Z","timestamp":1662220566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":69,"alternative-id":["10.3389\/fphar.2018.01030"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01030","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"article-number":"1030"}}